Johnson & Johnson Statement on Varipulse U.S. External Evaluation
January 10, 2025
January 10, 2025
NEW BRUNSWICK, New Jersey, Jan. 10 -- Johnson and Johnson issued the following agency statement on Jan. 8, 2025:
* * *
At Johnson & Johnson MedTech, the health and safety of our patients is our top priority. On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation. As . . .
* * *
At Johnson & Johnson MedTech, the health and safety of our patients is our top priority. On January 5, out of an abundance of caution, Johnson & Johnson MedTech temporarily paused the U.S. External Evaluation and all U.S. VARIPULSE cases while we investigate the root cause of four reported neurovascular events in the U.S. External Evaluation. As . . .